Plasma derivatives

Blood derivatives constitute a unique and separate group of speciality pharmaceutical products. Blood derivatives are defined as pharmaceutical products whose active ingredient is obtained from the plasma of healthy human donors through a process of separation (fractionation) and controlled purification.

The Banc de Sang i Teixits (Blood and Tissue Bank, BST) has signed a contract with the pharmaceutical industry to handle the fractionation of surplus donor plasma. Under the terms of this contract, the BST delivers its surplus plasma, and in exchange the industry supplies blood derivative drugs which we distribute to hospitals. 

The products that the BST obtains from its fractionated plasma are: 

Albutein® al 20%, 50 ml and 100 ml.

Human albumin 

Flebogamma® IV al 5%, 5 g and 10 g.

High-purity human immunoglobulin

Fanhdi® 100UI FVIII/120 UI FvW (10 ml).

Compound of human coagulation factor VIII and Von Willebrand factor

Factor IX Grífols® 50 UI/ml (20 ml)

Coagulation factor IX

Trypsone® 1 g.

Alpha-1-antitrypsin (AAT) concentrate with a high specific activity